Goal 3: Advance Translational Research

To facilitate innovation and accelerate research translation, knowledge dissemination, and implementation science that enhances public health.

Goal 3: Advance Translational Research

Novel Cell Apheresis Technologies to Treat Hematologic Diseases

Current FDA approved apheresis technology uses elutriation/centrifugation or filtration separation techniques to remove pathologic cellular and/or plasma elements. Currently these techniques are non-specific, limited by inefficient removal kinetics and often require considerable blood product exposure. Despite tremendous improvement in our understanding of the pathophysiology of a variety of disease, our ability to ...more »

Submitted by (@ewong0)

Voting

118 net votes
139 up votes
21 down votes
Active

Goal 3: Advance Translational Research

Public-Private Partnerships to Improve Nutrition & Reduce Obesity

How can we best encourage and support collaborations between academic researchers and industry partners to test strategies for changing nutritional choices and eating behaviors to healthier patterns that can improve obesity rates? Subquestions include issues around adopting healthier food choices in a variety of environments, effects of diet alteration, the methods and effects of enhancing healthier food flavors, understanding ...more »

Submitted by (@nhlbiforumadministrator1)

Voting

54 net votes
96 up votes
42 down votes
Active

Goal 3: Advance Translational Research

Improving Community-Based Care for Sickle Cell Disease

Sickle cell treatment centers are located throughout the United States, primarily in urban areas, and play an invaluable role. However, there is a critical need to identify and educate primary care providers who can provide routine and preventive care, but will also know when to consult with/refer to hematologists and other appropriate providers when necessary.

Submitted by (@nhlbiforumadministrator)

Voting

9 net votes
9 up votes
0 down votes
Active

Goal 3: Advance Translational Research

Development of Novel Apheresis Adsorption Technologies to More Effectively and Safely Treat Hematologic Diseases

Current FDA approved apheresis technology currently uses elutriation/centrifugation separation techniques to remove pathologic cellular and/or plasma elements. These techniques are non-specific, limited by inefficient removal kinetics and often require considerable blood product exposure. Despite tremendous improvement in our understanding of the pathophysiology of a variety of disease, our ability to treat many of ...more »

Submitted by (@ewong0)

Voting

93 net votes
112 up votes
19 down votes
Active

Goal 3: Advance Translational Research

Understanding heterogeneity in ARDS

ARDS is a syndrome, yet we treat it as though it was a single clinical disease. There has been success in improving the process of care for patients with ARDS, but no real progress on address the underlying process. For successful therapies to influence the disease process, we need to be able to distinguish the mechanisms active in individual patients and so that we can design and test interventions targeting the specific ...more »

Submitted by (@robert.paine)

Voting

0 net votes
3 up votes
3 down votes
Active